OBJECTIVE: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. STUDY DESIGN: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. RESULTS: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). CONCLUSION: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.
OBJECTIVE: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. STUDY DESIGN: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. RESULTS:GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). CONCLUSION:GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancerpatients with lower survival rates.
Authors: Yin-Yan He; Gui-Qiang Du; Bin Cai; Qin Yan; Long Zhou; Xiao-Yue Chen; Wen Lu; Yi-Xia Yang; Xiao-Ping Wan Journal: J Cancer Res Clin Oncol Date: 2012-01-24 Impact factor: 4.553
Authors: Jenna Z Marcus; Merieme Klobocista; Rouzan G Karabakhtsian; Eric Prossnitz; Gary L Goldberg; Gloria S Huang Journal: Int J Gynecol Cancer Date: 2018-03 Impact factor: 3.437
Authors: Eric A Ariazi; Eugen Brailoiu; Smitha Yerrum; Heather A Shupp; Michael J Slifker; Heather E Cunliffe; Michael A Black; Anne L Donato; Jeffrey B Arterburn; Tudor I Oprea; Eric R Prossnitz; Nae J Dun; V Craig Jordan Journal: Cancer Res Date: 2010-01-19 Impact factor: 12.701